DCTH

Delcath Systems, Inc. (DCTH) | Rumor.io

Delcath Systems

DCTH

Attention (50-day avg)0%

Attention rank (50-day avg)#2,353

Bullish sentiment (50-day avg)96%

Price to earnings ratio1.6K

Market capitalization548.6M

Earnings per share0.01

Dividend yield (TTM)—

Revenue (annual)85.2M

Net income (annual)2.7M

Social

What share of all stock conversation is about DCTH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 6

Delcath Systems, Inc. (DCTH) reported Q2 revenue of $29.1 million, beating consensus estimates.
The company raised its full-year guidance to a revenue range of $104 million to $108 million, with gross margins between 86% and 89% and positive adjusted EBITDA.
Delcath is expanding its indications into colorectal and breast cancer, as well as exploring new potential indications, including cutaneous melanoma.

Generated by AI

Sentiment

Of the messages about DCTH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	83.33% -16.67	95.65% +0.05	85.53% +5.7
Bearish	0%	16.67% +16.67	4.35% -0.05	14.47% -5.7

Bullish· Jun 11

$DCTH is showing strong bullish momentum with multiple posts highlighting its upward trajectory.
The Delcath Systems, Inc. chart is looking particularly strong, with several posts pointing to a robust performance.
$DCTH's bullish trend is expected to continue, with multiple posts expressing optimism about its future prospects.

Bearish· Jun 9

The price of the $DCTH 12.5 call option expiring 6/18 has risen to 0.50, indicating a potential short squeeze.
Investors are averaging down on their $DCTH 12.5 call positions, buying more options at the lower price to reduce their cost basis.
The recent buying activity in $DCTH 12.5 calls expiring 6/18 may be driven by a short squeeze, with some investors grabbing options at 0.50 each.

Generated by AI

Topics

Of the messages about DCTH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	33.33%	25.28%
Technical Analysis	—	—	66.67%	22.63%
Earnings	—	—	0%	10.27%
Analysts	—	—	0%	21.24%
Controversies	—	—	0%	0.88%
Macro	—	—	0%	19.7%

Earnings· Aug 8

$DCTH reported a 47% improvement in net loss, reducing it to $2 million from $6.7 million in the previous quarter.
The company's revenue increased, with a corresponding decrease in cost of goods sold, resulting in a smaller loss and almost breakeven results.
Delcath Systems reported a 44% increase in sales for the second quarter compared to the same period last year, with earnings per share improving by $4.40 per share.

Announcements· Aug 15

Delcath Systems, Inc. (DCTH) has announced FDA approval of HEPZATO KIT for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma.
The approval triggers additional funding of up to $34.9 million through a previously announced Private Investment in Public Equity (PIPE) financing.
The company's stock has surged following the FDA approval, with a 62% increase in pre-market trading and a closing price of $5.10.

Technical Analysis· Aug 15

The author notes that Delcath Systems (DCTH) tends to break out after the 10:30 HOD is violated, which can be a long trap if there's an S1 pending.
The asset is experiencing inflow bumps to higher highs but struggling to sustain value at the tops, with the author watching for a consolidation around $6.75 to $6.85 for a potential movement above $7.
The author is concerned that one of these pushes into highs will stuff all the buyers and likely jam down 2-3 hours of long traders in a candle, each time size hits the offer.

Generated by AI

Community

Of the messages about DCTH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	71.88%	38.12%
Newcomers	0%	0%	28.13%	61.88%

Regulars· Aug 6

Delcath Systems reports Q2 revenue of $29.1 million, beating consensus estimates of $26.26 million, and raises full-year guidance to a range of $104 million to $108 million.
The company's Q2 results include a GAAP EPS of $0.07, a 20.60% year-over-year increase in revenue, and a gross margin between 86% and 89% for the full year.
Regular participants are optimistic about the company's future, citing Gerard's conservative predictions and the stock's potential to slide through $20 on the next quarter's results.

Newcomers· Aug 6

Delcath Systems' ($DCTH) HEPZATO KIT is expanding into colorectal and breast cancer indications, with a potentially massive addressable market.
The company's Q2 2026 results showed strong revenue growth, driven by HEPZATO sales, with a 90% gross margin and net income of $2.7 million.
Delcath Systems is preparing for pre-IND meetings with the FDA to discuss new potential indications, including a new trial for cutaneous melanoma, which could further expand its addressable market.

Generated by AI

News

Are Medical Stocks Lagging Delcath Systems (DCTH) This Year?

Here is how Delcath Systems, Inc. (DCTH) and Encompass Health (EHC) have performed compared to their sector so far this year.

14d agoYahoo Finance

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y., September 11, 2026--Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either July 2026 or August 2026.

19d agoYahoo Finance

Delcath’s (DCTH) Liver Cancer Device Keeps Growing, But At A Cost

On August 6, Delcath Systems (NASDAQ:DCTH) reported second-quarter results that showed the company selling more of its liver cancer treatment than ever, even as the cost of running the business climbed just as fast. The interventional oncology company posted total revenue of $29.1 million, up from $24.2 million a year earlier, and used the report […]

19d agoYahoo Finance

Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services

EuroDry, RCM Technologies, Assembly Biosciences, Delcath Systems and National Energy Services show strong price momentum after August's market gains.

21d agoYahoo Finance

Delcath Systems to Participate in Upcoming Investor Conferences

QUEENSBURY, N.Y., August 31, 2026--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences:

1mo agoYahoo Finance

What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now?

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

1mo agoYahoo Finance

Also Discussed

Investors talking about DCTH also mention

#	Name	Attention
1	Xtant Medical Holdings Inc.XTNT	0%0
2	CEL-SCI CorporationCVM	0%0
3	DarkHorse Technologies Inc.ANY	0%new
4	Moleculin Biotech, Inc.MBRX	0%0
5	Dyne Therapeutics, Inc.DYN	0%+0
6	Omnicell, Inc.OMCL	0%0
7	Houston American Energy Corp.HUSA	0%new
8	Top Ships Inc.TOPS	0%+0
9	22nd Century Group Inc.XXII	0%0
10	ACER - Acer Therapeutics Inc.	——

Delcath Systems, Inc.

Healthcare
Medical Devices

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company develops and commercializes drug-device therapies designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure and related side effects. Its current product portfolio includes HEPZATO KIT in the United States and CHEMOSAT in Europe, both used in hepatic delivery procedures for liver cancer care. Delcath Systems serves specialized oncology centers and medical professionals that treat patients with liver tumors, positioning its technologies within the broader medical device and specialty pharmaceutical markets. Headquartered in Queensbury, New York, Delcath Systems plays a focused role in targeted cancer treatment by combining pharmaceutical and device-based approaches for liver-directed therapy.

Website

Location

566 Queensbury Avenue

Queensbury, NY, 12804

United States

Social

What share of all stock conversation is about DCTH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 6

Delcath Systems, Inc. (DCTH) reported Q2 revenue of $29.1 million, beating consensus estimates.
The company raised its full-year guidance to a revenue range of $104 million to $108 million, with gross margins between 86% and 89% and positive adjusted EBITDA.
Delcath is expanding its indications into colorectal and breast cancer, as well as exploring new potential indications, including cutaneous melanoma.

Generated by AI

Sentiment

Of the messages about DCTH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	83.33% -16.67	95.65% +0.05	85.53% +5.7
Bearish	0%	16.67% +16.67	4.35% -0.05	14.47% -5.7

Bullish· Jun 11

$DCTH is showing strong bullish momentum with multiple posts highlighting its upward trajectory.
The Delcath Systems, Inc. chart is looking particularly strong, with several posts pointing to a robust performance.
$DCTH's bullish trend is expected to continue, with multiple posts expressing optimism about its future prospects.

Bearish· Jun 9

The price of the $DCTH 12.5 call option expiring 6/18 has risen to 0.50, indicating a potential short squeeze.
Investors are averaging down on their $DCTH 12.5 call positions, buying more options at the lower price to reduce their cost basis.
The recent buying activity in $DCTH 12.5 calls expiring 6/18 may be driven by a short squeeze, with some investors grabbing options at 0.50 each.

Generated by AI

Topics

Of the messages about DCTH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	33.33%	25.28%
Technical Analysis	—	—	66.67%	22.63%
Earnings	—	—	0%	10.27%
Analysts	—	—	0%	21.24%
Controversies	—	—	0%	0.88%
Macro	—	—	0%	19.7%

Earnings· Aug 8

$DCTH reported a 47% improvement in net loss, reducing it to $2 million from $6.7 million in the previous quarter.
The company's revenue increased, with a corresponding decrease in cost of goods sold, resulting in a smaller loss and almost breakeven results.
Delcath Systems reported a 44% increase in sales for the second quarter compared to the same period last year, with earnings per share improving by $4.40 per share.

Announcements· Aug 15

Delcath Systems, Inc. (DCTH) has announced FDA approval of HEPZATO KIT for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma.
The approval triggers additional funding of up to $34.9 million through a previously announced Private Investment in Public Equity (PIPE) financing.
The company's stock has surged following the FDA approval, with a 62% increase in pre-market trading and a closing price of $5.10.

Technical Analysis· Aug 15

The author notes that Delcath Systems (DCTH) tends to break out after the 10:30 HOD is violated, which can be a long trap if there's an S1 pending.
The asset is experiencing inflow bumps to higher highs but struggling to sustain value at the tops, with the author watching for a consolidation around $6.75 to $6.85 for a potential movement above $7.
The author is concerned that one of these pushes into highs will stuff all the buyers and likely jam down 2-3 hours of long traders in a candle, each time size hits the offer.

Generated by AI

Community

Of the messages about DCTH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	71.88%	38.12%
Newcomers	0%	0%	28.13%	61.88%

Regulars· Aug 6

Delcath Systems reports Q2 revenue of $29.1 million, beating consensus estimates of $26.26 million, and raises full-year guidance to a range of $104 million to $108 million.
The company's Q2 results include a GAAP EPS of $0.07, a 20.60% year-over-year increase in revenue, and a gross margin between 86% and 89% for the full year.
Regular participants are optimistic about the company's future, citing Gerard's conservative predictions and the stock's potential to slide through $20 on the next quarter's results.

Newcomers· Aug 6

Delcath Systems' ($DCTH) HEPZATO KIT is expanding into colorectal and breast cancer indications, with a potentially massive addressable market.
The company's Q2 2026 results showed strong revenue growth, driven by HEPZATO sales, with a 90% gross margin and net income of $2.7 million.
Delcath Systems is preparing for pre-IND meetings with the FDA to discuss new potential indications, including a new trial for cutaneous melanoma, which could further expand its addressable market.

Generated by AI

Delcath Systems

Social

Aug 6

Bullish· Jun 11

Bearish· Jun 9

Earnings· Aug 8

Announcements· Aug 15

Technical Analysis· Aug 15

Regulars· Aug 6

Newcomers· Aug 6

Are Medical Stocks Lagging Delcath Systems (DCTH) This Year?

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath’s (DCTH) Liver Cancer Device Keeps Growing, But At A Cost

Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services

Delcath Systems to Participate in Upcoming Investor Conferences

What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now?

Also Discussed

Delcath Systems, Inc.

Company Information

Location

Are Medical Stocks Lagging Delcath Systems (DCTH) This Year?

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath’s (DCTH) Liver Cancer Device Keeps Growing, But At A Cost

Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services

Delcath Systems to Participate in Upcoming Investor Conferences

What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now?

Also Discussed

Social

Aug 6

Bullish· Jun 11

Bearish· Jun 9

Earnings· Aug 8

Announcements· Aug 15

Technical Analysis· Aug 15

Regulars· Aug 6

Newcomers· Aug 6